In the intricate landscape of the healthcare industry, public discourse surrounding drug pricing frequently begins and ends with the list…
Read More
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly’s investigational drug, retatrutide, a pioneering first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, has delivered extraordinary results…
Read More
Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025
Eli Lilly and Company has achieved a historic milestone, concluding fiscal year 2025 as the world’s highest-earning pharmaceutical company by…
Read More
MEDVi’s Meteoric AI-Fueled Ascent Faces Scrutiny Amidst FDA Warnings, Allegations of Deceptive Marketing, and Multiple Lawsuits
A telehealth startup, MEDVi, recently lauded by The New York Times as a prime example of an AI-driven billion-dollar enterprise,…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
Merck’s Keytruda (pembrolizumab), a cornerstone of modern oncology, maintained its position as the pharmaceutical industry’s leading brand in Fiscal Year…
Read More
Pharma 50: The 50 best-selling drugs of FY2025
The pharmaceutical industry in Fiscal Year 2025 was defined by a dynamic interplay of enduring blockbuster powerhouses and the dramatic…
Read More
Lilly Ascends to Pharma’s Top Revenue Spot Amidst Landmark Oral GLP-1 Approval, Yet Wall Street Remains Unconvinced
Eli Lilly and Company has officially claimed the top spot among global pharmaceutical companies by revenue, a monumental achievement underscored…
Read More
Engineered exosomes from pig semen: a high-yield platform for non-invasive ocular drug delivery
Researchers in China have achieved a significant breakthrough in ophthalmic pharmacology, developing innovative eye drops derived from pig semen that…
Read More
Sai Life Sciences Hosts Landmark Biotech Pitch Day 2026 in Boston, Forging Critical Alliances for Future Drug Discovery
Boston, MA – Sai Life Sciences, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), recently convened its highly…
Read More
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
The burgeoning market for obesity treatments, now valued at an astonishing $1 trillion, stands at a pivotal juncture. While GLP-1…
Read More
